Abstract
Capecitabine, a fluoropyrimidine derivative, is an orally administered drug that delivers 5-fluorouracil (5-FU) selectively to the tumour. The drug has demonstrated activity in metastatic colorectal cancer. We describe a male patient receiving capecitabine therapy with typical chest pain and electrocardiographic changes consistent with STsegment elevation myocardial infarction. Capecitabine-induced cardiotoxicity may develop in patients who have had a previous episode of 5-FU-induced cardiotoxicity. Capecitabine-induced cardiotoxicity is a rare condition that may lead to diagnostic and therapeutic dilemmas. (Neth Heart J 2009;17:277–80.)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57:475–84.
McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Exp Opin 2005;6:231–9.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.
Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263–302.
Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181–91.
Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405–10.
Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704–12.
Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217–36.
Schnetzler B, Popola N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol 2001;12:723–4.
Bertolini A, Fumano M, Fusco O, Muffatti A, Scarinci A, Pontiggia G, et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001;87:200–6.
Desramé J, Bronstein JA, Thiolet C, Bredin C, Ceccaldi B, Vergeau B, et al. Coronary insufficiency after an oral intake of capecitabine. Gastroenterol Clin Biol 2001;25:829–30.
Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrash H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002;13:795–801.
Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J. Capecitabine induces severe angina-like chest pain. Ann Intern Med 2004;140:494–5.
Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885–9.
Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracilinduced coronary vasospasm with calcium channel blockers. Am J Med 1998;85:750–1.
Author information
Authors and Affiliations
Corresponding author
Additional information
Department of Cardiology, Uludag University School of Medicine, Görükle, Bursa, Turkey
T. Şentürk Uludağ Üniversitesi Tip Fakültesi Kardiyoloji Anabilim Dali, 16059, Görükle, Bursa, Turkey
Rights and permissions
About this article
Cite this article
Şentürk, T., Kanat, Ö., Evrensel, T. et al. Capecitabine-induced cardiotoxicity mimicking myocardial infarction. NHJL 17, 277–280 (2009). https://doi.org/10.1007/BF03086265
Issue Date:
DOI: https://doi.org/10.1007/BF03086265